ARYx slashes workforce after licensing talks break down
19 February 2010
Simon Varcoe
Please Login to read the full article.
19 February 2010
Simon Varcoe
simon.varcoe@informa.com
ARYx Therapeutics has reduced its workforce to less than 20 employees after licensing talks with other companies concerning its oral antiarrythmic agent budiodarone (ATI-2042) fell through.
ARYx, which reduced its staff from 73 employees to 56 in November, has retained the investment bank...
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA advisers back J&J-Bayer stroke drug, but call for warfarin transition testing
- US FDA drug reviewers advise against approval of J&J-Bayer stroke drug
- Mundipharma pays Allos $50 million up front for ex-US rights to lymphoma drug
- US Capitol Capsule: Group proposes efforts to ensure US innovation competitiveness
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
